MedCity Influencers

Stent-based therapy developer TriReme Medical lands $17M

TriReme Medical Inc. completed its $17 million Series D financing round. Bio*One Capital PTE LTD […]

TriReme Medical Inc. completed its $17 million Series D financing round.

Bio*One Capital PTE LTD led the financing; current investors Three Arch Partners and Adams Street Partners also contributed “strong support,” according to Singapore-based Bio*One’s parent company EDB Investments PTE LTD.

The funding will support TriReme‘s product commercialization and development efforts in Asia, according to EDBI.

“This investment will allow us to ramp up our commercial activities worldwide, continue to develop internal R&D programs and pursue key regulatory approvals for our products in large markets such as the U.S., Japan and China,” CEO Eitan Konstantino said.

The Pleasanton, California-based company develops balloon and stent-based therapies for for the treatment of coronary and peripheral artery disease.


MassDevice Staff

The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.

Shares0
Shares0